1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Pérez-García JM, Gion M, Ruiz-Borrego M, Blancas I, López-Miranda E, Blanch S, Recalde S, Rendo CR, González X, Ancizar N, Morales S, Cortez P, Piwowarska Z, Shimizu E, Guerrero JA, Sampayo-Cordero M, Martínez-Bueno A, Cortés J, Llombart-Cussac A.

    Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

    Eclinicalmedicine . 85: 103309-103309. Nº de citas: 1

    [doi:10.1016/j.eclinm.2025.103309]

  • Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F.

    Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

    Annals of oncology : official journal of the European Society for Medical Oncology . 36(7): 832-837.

    [doi:10.1016/j.annonc.2025.03.010]

  • Gorospe L, Saavedra-Serrano C, Martínez-Jáñez N.

    Eribulin-induced pulmonary toxicity mimicking metastatic lung disease.

    MEDICINA CLINICA . 165(1): 106993-106993.

    [doi:10.1016/j.medcli.2025.106993]

  • Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M.

    Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON-1 study

    CANCER IMMUNOLOGY IMMUNOTHERAPY . 74(7): 196-196.

    [doi:10.1007/s00262-025-04019-x]

  • Alonso-Gordoa T, Anguera G, Domínguez-Esteban M, Reig Ò, Martínez-Barros H, Molina-Cerrillo J, Cruz P, Maroto P.

    Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.

    CANCER TREATMENT REVIEWS . 136: 102925-102925.

    [doi:10.1016/j.ctrv.2025.102925]

  • Herranz-Montoya I, Angulo-Aguado M, Perna C, Zagorac S, García-Jimeno L, Park S, Djouder N.

    p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer

    NATURE COMMUNICATIONS . 16(1): 3934-3934. Nº de citas: 3

    [doi:10.1038/s41467-025-59282-4]

  • Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Viñuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-García M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taïeb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Álvarez-Álvarez R, Lousberg L, Aboubakar Nana F, Hernando J, García-Álvarez A, García-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A.

    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)

    Bmc Cancer . 25(1): 613-613. Nº de citas: 3

    [doi:10.1186/s12885-025-13941-3]

  • Borque-Fernando Á, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Pérez-Fentes DA, Vilaseca A, Agut CM, Usán P, Rey PM.

    Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC

    FUTURE ONCOLOGY . 21(8): 991-1003. Nº de citas: 2

    [doi:10.1080/14796694.2025.2468569]

  • López-Miranda E, Tolosa-Ortega P, Perelló-Martorell MA, Sánchez-Lorenzo L, Hinojo-González C, Servitja S, Recalde-Penabad S, Olier-Gárate C, Guerrero JA, García-Vicente S, Mina L, Alcalá-López D, López-Montero L, Jiménez-Cortegana C, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.

    Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

    Esmo Real World Data And Digital Oncology . 7: 100107-100107.

    [doi:10.1016/j.esmorw.2024.100107]

  • Fernández-Abad M, Caniego-Casas T, Carretero-Barrio I, Calderay-Domínguez M, Saavedra C, Hardisson D, Palacios J, Pérez-Mies B.

    Ipsilateral Breast Carcinoma Recurrence

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 49(3): 294-302. Nº de citas: 1

    [doi:10.1097/PAS.0000000000002351]

  • Cortés-Salgado A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, Cristóbal E, Del Campo-Albendea L, Guerra E, Alía V, de Aguado PP, Corraliza V, Palacios J, Pérez-Mies B.

    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study

    GYNECOLOGIC ONCOLOGY . 194: 33-40. Nº de citas: 5

    [doi:10.1016/j.ygyno.2025.02.005]

  • Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, Albillos A.

    Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort

    JOURNAL OF HEPATOLOGY . 82(3): . Nº de citas: 10

    [doi:10.1016/j.jhep.2024.09.005]

  • Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E.

    Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study

    EUROPEAN JOURNAL OF CANCER . 217: 115219-115219. Nº de citas: 3

    [doi:10.1016/j.ejca.2024.115219]

  • Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Mackowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS.

    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.

    EUROPEAN JOURNAL OF CANCER . 216: 115146-115146.

    [doi:10.1016/j.ejca.2024.115146]

  • González-Martínez S, Palacios J, Carretero-Barrio I, Lanza VF, García-Cosío Piqueras M, Caniego-Casas T, Hardisson D, Esteban-Rodríguez I, Cortés J, Pérez-Mies B.

    Single-Cell RNA Sequencing on Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Identified Multi-Ciliary Cells in Breast Cancer

    Cells . 14(3): .

    [doi:10.3390/cells14030197]

  • Palacios P, Palacios I, Palacios A, Lorente A, Mariscal G, Benlloch M, Palacios J.

    Effect of bariatric surgery on postoperative outcomes of total hip arthroplasty: An updated systematic review and meta-analysis

    ASIAN JOURNAL OF SURGERY . 48(2): 979-985. Nº de citas: 3

    [doi:10.1016/j.asjsur.2024.11.003]

  • Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I.

    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ ENGOT-ov25 trial

    Annals of oncology : official journal of the European Society for Medical Oncology . 36(2): 185-196. Nº de citas: 16

    [doi:10.1016/j.annonc.2024.10.828]

  • Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B.

    Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

    JOURNAL OF CLINICAL ONCOLOGY . 43(3): 2400920-2400920. Nº de citas: 79

    [doi:10.1200/JCO.24.00920]